Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02679196 · ClinicalTrials.gov registry record · Phase 1

The Safety, Pharmacokinetic and Pharmacodynamic Effect of KA2237 (PI3 Kinase p110β/δ Inhibitor) In B Cell Lymphoma

A Phase 1 study of Lymphoma, B-Cell, sponsored by Karus Therapeutics Limited.

Completed
Registry status
Phase 1
Development phase
23
Enrollment target
1
Study location

NCT02679196 is a Phase 1 study of Lymphoma, B-Cell that has completed, run by Karus Therapeutics Limited. The registered enrollment target is 23 participants, below the 201-participant average among 31 other Lymphoma, B-Cell trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02679196, a Phase 1 study of Lymphoma, B-Cell, has completed, sponsored by Karus Therapeutics Limited.

COMPLETED
Registry status
Phase 1
Development phase
23 participants
Enrollment target
1
Study location

Study Summary

Multiple ascending dose study to evaluate safety/tolerability, pharmacokinetic and pharmacodynamics effects of KA2237 (PI3 Kinase p110β/δ Inhibitor) in patients with B Cell Lymphoma and determine the maximum tolerated dose (MTD) in Part I of the study. In Part II, patients with B cell lymphoma will be treated with KA2237 at the MTD to evaluate safety and efficacy in the patient population.

Conditions Studied

Lymphoma, B-Cell

Interventions

  • DRUG KA2237

Study Locations (1)

Texas

  • MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 23 participants
Start Date 2016-07
Est. Completion 2018-12-24
Phase Phase 1

Sponsor

Karus Therapeutics Limited

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02679196

The ClinicalTrials.gov registry entry for NCT02679196 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 201-participant average among 31 other Lymphoma, B-Cell trials with a reported enrollment target (89% lower). The listed sponsor is Karus Therapeutics Limited, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Lymphoma, B-Cell appearing as the primary indexed condition, and to 1 intervention - of which KA2237 is the first listed.

NCT02679196 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT02679196 about?

NCT02679196 is a clinical study titled "The Safety, Pharmacokinetic and Pharmacodynamic Effect of KA2237 (PI3 Kinase p110β/δ Inhibitor) In B Cell Lymphoma". Multiple ascending dose study to evaluate safety/tolerability, pharmacokinetic and pharmacodynamics effects of KA2237 (PI3 Kinase p110β/δ Inhibitor) in patients with B Cell Lymphoma and determine the maximum tolerated dose (MTD) in Part I of the study. In Part II, patients with B cell lymphoma will ...

What is the current status of trial NCT02679196?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2016-07. Estimated completion is 2018-12-24.

What conditions does trial NCT02679196 study?

This clinical trial studies the following conditions: Lymphoma, B-Cell.

What interventions are being tested in trial NCT02679196?

The interventions under investigation include: KA2237 (DRUG).

Who is sponsoring clinical trial NCT02679196?

This trial is sponsored by Karus Therapeutics Limited, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02679196 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lymphoma, B-Cell

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Lymphoma, B-Cell

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.